- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of October 7
The Center for Biosimilars® recaps the top stories for the week of October 7, 2019.
Transcript
Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of October 7, 2019.
Number 5: A new study reports that, for children who switch to biosimilars, factors like device type, citrates, and even color can be primary concerns.
Number 4: The Institute for Clinical and Economic Review says that brand-name adalimumab, rituximab, and pegfilgrastim, all of which have approved biosimilars, have seen substantial increases to price that have not been supported by new clinical data.
Number 3: Nevada’s Department of Health and Human Services sent letters to drug firms that did not provide required information about their costs, and it issued $17.4 million in penalties for noncompliance.
Number 2: The FDA has approved Pfenex’s follow-on teriparatide, referencing Forteo, for the treatment of osteoporosis.
Number 1: The FDA has issued a complete response letter for Tanvex’s proposed filgrastim biosimilar.
Finally, last week, our e-newsletter asked whether you think that the United States should allow external reference pricing to help reduce drug costs.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
